Jounce Therapeutics, Inc. engages in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Its immunotherapies are designed to harness the patient's immune system to seek out and attack cancerous cells and tumors. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.
1030 Massachusetts Avenue
Cambridge, MA 02138
Founded in 2012
Jounce Therapeutics Appoints Perry Karsen to its Board
Jan 21 16
Jounce Therapeutics, Inc. announced the appointment of Perry A. Karsen to the company's board of directors. Over the next few months Mr. Karsen will transition to the role of chairman of the board, succeeding Cary Pfeffer, M.D., partner at Third Rock Ventures, who will retain a position on the Jounce board. Mr. Karsen brings more than 30 years of experience in the biopharmaceutical industry and recently retired from his role as chief executive officer of Celgene Cellular Therapeutics (CCT), the cell therapy research and development division of Celgene Corporation. Mr. Karsen served as the chief executive officer of CCT since May 2013, previously serving as Celgene Corporation's executive vice president and chief operations officer.
Jounce Therapeutics Appoints Duncan Higgons to its Board of Directors
Nov 17 15
Jounce Therapeutics, Inc. announced Duncan Higgons has been appointed to the company’s board of directors. Mr. Higgons has served as the chief operating officer at Agios Pharmaceuticals since 2009.
Jounce Therapeutics, Inc. Appoints Elizabeth Trehu as Chief Medical Officer
Nov 3 15
Jounce Therapeutics, Inc. announced the appointment of Elizabeth Trehu, M.D., to the position of chief medical officer. Dr. Trehu brings to Jounce more than 25 years of clinical experience, including nearly 15 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu joins the company from Promedior, Inc., where she served as the chief medical officer. In this role, she was responsible for clinical development, clinical operations, regulatory affairs, quality assurance and program management, and led the creation and mplementation of clinical development plans for Promedior’s lead product candidate. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme’s transplant oncology group. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE. As an assistant professor of medicine at Tufts University School of Medicine, Dr. Trehu conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group.